Metformin modifies disparity in hepatocellular carcinoma incidence in men with type 2 diabetes but without chronic liver diseases

ConclusionsIn men with T2D but without CLD nor metformin use, HCC incidence was lower for NHAA compared to NHW or Hispanics; similar between NHW and Hispanics. Metformin use reduced HCC risk and modified the race/ethnicity disparity.ImpactMetformin's heterogeneous HCC prevention effect elucidates potential interventions to modify HCC disparity in patients with T2D.

Source: Cancer Medicine - April 15, 2019 Category: Cancer & Oncology Authors: Chen ‐Pin Wang, John Kuhn, Dimpy P. Shah, Susanne Schmidt, Yui‐Wing F. Lam, Daniel MacCarthy, Laura Tenner, Amelie G. Ramirez Tags: ORIGINAL RESEARCH Source Type: research